Posted by Michael Wonder on 12 May 2020
Moderna receives FDA fast track designation for mRNA vaccine (mRNA-1273) against novel voronavirus
12 May 2020 - Finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.
Moderna today announced that the U.S. FDA has granted fast track designation for the Company’s mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).
